Eaton to showcase comprehensive commercial vehicle clutch portfolio at Automechanika Frankfurt
5.9.2024 12:30:00 CEST | Business Wire | Press release
Intelligent power management company Eaton today announced it is showcasing an array of aftermarket clutch solutions for the Europe, Middle East and Africa (EMEA) markets at Automechanika Frankfurt in Hall 3, booth D11. Eaton is displaying its complete line of angle spring clutches, diaphragm spring clutches, concentric pneumatic clutch actuators and ServiceRanger diagnostic solutions for commercial vehicles.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240905507731/en/
Eaton’s Advantage series automated diaphragm spring clutches are designed for all makes and models of automated manual transmissions (AMT) in the EMEA market. (Photo: Business Wire)
“We are dedicated to expanding our product portfolio to meet the changing needs of the global market and increasing customer relationships in all market channels,” said Tim Bauer, vice president, Aftermarket, Eaton’s Mobility Group.
The angle spring clutches are used for manual transmissions and are offered in two series. The Advantage series features strap drive technology that improves intermediate plate connection for more reliable performance while eliminating lug rattle and fatigue. Additionally, they are designed with a dual-seal release bearing, which allows for best-in-class 80,000-km lube intervals, reducing maintenance downtime. Eaton also offers the EverTough® series, which provides a more cost-effective solution for vehicles older than seven years.
Eaton also will be displaying its Advantage series automated diaphragm spring clutches for all makes and models of automated manual transmissions (AMT) in the EMEA market. These clutches are built to strict OEM quality standards and minimize idling noise while reducing severe vibrations and delivering outstanding performance and extended clutch life.
Eaton will also be showing its electronic clutch actuator that is designed for its UltraShift Plus transmission along with its concentric pneumatic clutch actuators (CPCAs) for DT12®, the Volvo I-Shift and Mack mDRIVE™ AMTs. The CPCAs help optimize vehicle performance by working with a vehicle’s AMT to continuously determine the ideal release position and clutch actuation when the transmission shifts. Many current AMT-equipped trucks are no longer under factory warranty, so fleet customers need reliable parts to complete repairs and maintenance. Replacing the CPCA during clutch service can help save repair time and cost while reducing downtime for unscheduled maintenance.
To support AMTs operating in the market Eaton offers its ServiceRanger™ 4 Pro Plus (SR4 Pro Plus) software. This diagnostic software and service tool is designed to support all Eaton AMTs, hybrid powertrain systems, Advantage Automated Series clutches and Eaton Cummins Automated Transmission Technologies. In addition, there is an “App Center” that allows users to calibrate all makes and models of diaphragm spring clutches and CPCAs that fit DT12®, Volvo® I-Shift and Mack mDRIVE™ AMTs.
“Eaton now offers a complete line of aftermarket clutch products in EMEA for all makes and models of trucks. Whether the truck is one year old or over fifteen years old, we have the clutch portfolio to provide our customers with cost effective solutions to keep their vehicle operating,” said Pawel Kepka, director, Aftermarket EMEA, Eaton’s Mobility Group.
Learn more about Eaton’s aftermarket solutions.
Eaton is an intelligent power management company dedicated to protecting the environment and improving the quality of life for people everywhere. We make products for the data center, utility, industrial, commercial, machine building, residential, aerospace, and mobility markets. We are guided by our commitment to do business right, to operate sustainably, and to help our customers manage power ─ today and well into the future. By capitalizing on the global growth trends of electrification and digitalization, we’re accelerating the planet’s transition to renewable energy sources, helping to solve the world’s most urgent power management challenges, and building a more sustainable society for people today and generations to come.
Eaton was founded in 1911 and has been listed on the New York Stock Exchange for more than a century. We reported revenues of $23.2 billion in 2023 and serve customers in more than 160 countries. For more information, visit www.eaton.com. Follow us on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240905507731/en/
Contacts
Thomas Nellenbach
Thomas Nellenbach
(216) 333-2876 (cell)
thomasjnellenbach@eaton.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom